Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB

Published on November 3, 2025
Cellistic_ft image_Pulse bridging the gap

Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.

Continue reading on website
Other news

Science in Person: Our experts make the difference

November 3, 2025
At Cellistic, our people are at the heart of turning iPSC-derived cell therapies into clinical reality.In this series, we meet the experts who make the difference — sharing their insights, challenges, and what drives them every day.

Real-world data in 2025 and beyond: Closing the strategy gap

November 3, 2025
Pharma leaders agree that real-world data (RWD) is essential—but many still struggle to harness its full potential. In Real-World Data in 2025 and Beyond: Closing the Strategy Gap, Norstella surveyed 200 life sciences executives to uncover how organizations are using RWD, where they’re falling short, and what separates high-performing strategies from the rest. The findings […]